FDA isn't recommending label change for ADHD drugs

04/10/2011 | Reuters

The FDA is not requiring drugmakers to change usage and safety information for Shire's Adderall XR, Novartis' Ritalin and other stimulants for attention-deficit/hyperactivity disorder. The agency said it will provide an update after it finishes analyzing ADHD drugs' potential risk of cardiovascular events.

View Full Article in:

Reuters

Published in Brief:

SmartBrief Job Listings for Health Care

Job Title Company Location
Catheter Engineer Manager
ASAHI INTECC, Orange County CA R&D Center
Santa Ana, CA
Neurovascular Intervention Product Sales Rep, North East
ASAHI INTECC
Multiple Locations, SL_Multiple Locations
Senior Manager, Compliance
Stryker
Fremont, CA
Director, Office of Device Evaluation
FDA, Center for Devices and Radiological Health
Silver Spring, MD
Director, Office of Compliance
FDA, Center for Devices and Radiological Health
Silver Spring, MD